Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors

Citation
E. Hermans et Raj. Challiss, Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors, BIOCHEM J, 359, 2001, pp. 465-484
Citations number
228
Categorie Soggetti
Biochemistry & Biophysics
Journal title
BIOCHEMICAL JOURNAL
ISSN journal
02646021 → ACNP
Volume
359
Year of publication
2001
Part
3
Pages
465 - 484
Database
ISI
SICI code
0264-6021(20011101)359:<465:SSARPO>2.0.ZU;2-4
Abstract
In 1991 a new type of G-protein-coupled receptor (GPCR) was cloned, the typ e 1a metabotropic glutamate (mGlu) receptor, which, despite possessing the defining seven-transmembrane topology of the GPCR superfamily, bore little resemblance to the growing number of other cloned GPCRs. Subsequent studies have shown that there are eight mammalian mGlu receptors that, together wi th the calcium-sensing receptor, the GABAB receptor (where GABA is gamma -a minobutyric acid) and a subset of pheromone, olfactory and taste receptors, make up GPCR family C. Currently available data suggest that family C GPCR s share a number of structural, biochemical and regulatory characteristics, which differ markedly from those of the other GPCR families, most notably the rhodopsin/family A GPCRs that have been most widely studied to date. Th is review will focus on the group I mGlu receptors (mGlu1 and mGlu5). This subgroup of receptors is widely and differentially expressed in neuronal an d glial cells within the brain, and receptor activation has been implicated in the control of an array of key signalling events, including roles in th e adaptative changes needed for long-term depression or potentiation of neu ronal synaptic connectivity. In addition to playing critical physiological roles within the brain, the mGlu receptors are also currently the focus of considerable attention because of their potential as drug targets for the t reatment of a variety of neurological and psychiatric disorders.